Companies Related to "Cytochrome P450 11B2 Mitochondrial Aldosterone Synthase Cytochrome P450Aldo" [Most Relevant Company Matches] RSS

05:12 EST 21st February 2019 | BioPortfolio

Here are the most relevant search results for "Cytochrome P450 11B2 Mitochondrial Aldosterone Synthase Cytochrome P450Aldo" found in our extensive corporate database of over 50,000 company records.

Showing "Cytochrome P450 11B2 Mitochondrial Aldosterone Synthase Cytochrome P450Aldo" Companies 1–25 of 37

Extremely Relevant

PanVera Corporation

Protein Kinase C Assays Androgen Receptor, Ligand Binding Domain Estrogen Receptor-Beta 1, Long Form Tau Protein, microtubule-associated protein, histidine-tagged Cytochrome P450 Monoclonal Antibodiesa broad selection of antibodies can be found here.

Affinity Bioreagents Incorporated

Apoptosis Related Antibodies Bioactive Peptide Antibodies Chaperonin Antibodies Cytochrome P450 Antibodies Heat Shock Protein Antibodies Immunophilin Antibodies Ion Transport Protein Antibodies Lipid Metabolism Antibodies Neurobiology AntiContract

Cyterix Pharmaceutics, Inc.

Cyterix Pharmaceutics, Inc., a privately held cancer therapeutics company, is engaged in the discovery and development of new classes of small molecule prodrugs with improved safety and efficacy over traditional drugs. The company’s approach, based on a proprietary technology platform, uniquely enables the design of multiple classes of anticancer p...

XenoTech, LLC

XenoTech's reputation as a leader in drug metabolism research originated in 1983 with Dr. Andrew Parkinson's studies of cytochrome P450 (CYP) enzymes. Dr. Parkinson founded XenoTech in 1994 to provide products and contract research services to optimize the discovery, development and approval of drugs, food additives, nutraceuticals, agrochemicals, cosmetics and fragrances. XenoTech's products and ...


Astex Technology Limited

Astex Technology is a structure-based drug discovery company pioneering the use of high throughput X-ray crystallography for the rapid identification of novel drug candidates. The company's unique structural screening approach utilizes protein crystal structures to detect the binding of drug fragments, which are then optimized into potent lead compounds. Facilitating this approach is the company...

Verne Mendel Medical Corp.

Verne Mendel Medical Corp. is a privately held biopharmaceutical company working on utilizing the highly mature knowledge base of the mitochondrial genome, developed by medical science during the past quarter century. By contrast it may take several decades of further research to reach a comparable level of understanding of the nuclear genome and the proteins it codes for. This knowledge includes...

The Foundation for Mitochondrial Medicine

The Foundation for Mitochondrial Medicine is a 501(c) (3) non-profit organization dedicated to supporting the development of the most promising research and treatments of the many forms of mitochondrial disease. Visit for more information.

GenSight Biologics S.A.

GenSight Biologics S.A. (GenSight) is a clinical-stage biotechnology company discovering and developing novel therapies for mitochondrial and neurodegenerative diseases of the eye, and in the future, of the central nervous system. GenSight’s integrated development includes two core technology platforms, mitochondrial targeting sequence (MTS) and optog...

Mitobridge, Inc.

Mitobridge is a leader in the emerging field of mitochondria-related drug discovery and development. The Company is utilizing its innovative screening platform to identify and develop novel therapeutics that improve mitochondria function and provide treatments for mitochondrial genetic diseases, musculoskeletal, kidney and neurodegenerative disorders as we...


MitoSciences was founded in 2004 by Dr. Roderick Capaldi and Dr. Michael Marusich with the mission of advancing mitochondrial research, and in particular, efforts to understand the role of the organelle in human diseases. The Company has produced and continues to add to the world's largest collection of anti-mitochondrial monoclonal antibodies. These antibodies are being sold for life sciences r...


MitoKor is Pioneering Mitochondrial Medicine™ by developing therapeutic solutions for diseases, based on mitochondrial research. Mitochondria are the self-charging batteries of cells, driving energy production, metabolism, and cellular life and death, as well as participating in other key signaling pathways. Mitochondria also house the "other" human genome, inherited only from the mother. Mitoch...

Foundation for Mitochondrial Medicine (FMM)

NeurAxon, Inc.

NeurAxon, Inc. ( discovers and develops next-generation pain therapeutics focused on its first-in-class selective inhibitors of neuronal nitric oxide synthase (nNOS), an enzyme involved in modulating pain and central nervous system neuronal sensitization.

NeurAxon Inc.

NeurAxon, Inc. ( discovers and develops next-generation pain therapeutics focused on its first-in-class selective inhibitors of neuronal nitric oxide synthase (nNOS), an enzyme involved in modulating pain and central nervous system neuronal sensitization.

United Mitochondrial Disease Foundation

Puracyp, Inc.

Puracyp began operations in 1993 focusing on the distribution of monospecific inhibitory antibodies to several human P450 enzymes. Members of the pharmaceutical industry used these antibodies to assess the contribution of a single P450 enzyme to a drug metabolizing reaction. Researchers also used anti-human P450 immunoglobulins in Western blotting experiments to determine expression of individual ...

The Alzheimer’s Drug Discovery Foundation (ADDF) and the Foundation for Mitochondrial Medicine (FMM)

Probably Relevant

Detroit R&D, Inc

Detroit R&D, Inc. was founded in 1997 by Dr. Hyesook Kim as a company dedicated to building a relationship of trust with the research community, by providing the highest quality products through leading-edge technology. Detroit R&D specializes in environmental health-, hypertension- and cancer-related research, including biologically active eicosanoids such as EETs and DHETs, prostaglandin H synth...

Gencia Corp.

Gencia Corp. is a privately held company focused on the discovery and development of first-in-class therapeutics for important medical needs, based on proprietary mitochondrial targeting technology and novel insights into the role of mitochondria in human health, aging, and disease. For more information on the company, please visit our website at http://ww...


Poxel uses its development expertise in metabolism to advance a pipeline of drug candidates focused on the treatment of metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH). We have successfully completed the Phase 2 clinical program for our first-in-class lead product, Imeglimin, which targets mitochondrial dysfunction, ...

LOH KEH CHUAN Diabetes, Thyroid & Hormone Clinic

Diabetesincludes on-site HbA1c and urine microalbumin testing, diabetes education, treatment of diabetes in pregnancy and diabetes-related complications Thyroid disordersincludes bedside thyroid ultrasound and fine needle aspiration of thyroid nodules, ultrasound-guided ethanol ablation of thyroid cysts, direct prescription for radio-active iodine treatment of thyroid diseases, treatment of thyroi...


Bactevo has built a unique and game-changing Totally Integrated Medicines Engine (TIME) to create novel therapeutics. Utilising its paradigm shift in the speed, efficiency and quality of drug discovery, as well as massively enhancing safety profiling to improve clinical success, Bactevo is developing breakthrough medicines for the treatment of diseases tha...


Critisense's first generation product - the "CritiView" is an innovative patient monitoring system providing real-time continuous information via four physiological parameters, sensed at the tissue level, reflecting the systemic metabolic state. CritiView is the only device providing continuous, real-time multi-parametric physiological data at the tissue and cellular level, by monitoring the mitoc...

CohBar, Inc.

CohBar (TSXV: COB.U) is the leader in the research and development of mitochondria-based therapeutics (MBTs), a new class of drugs for the treatment of diseases associated with aging. MBTs originated from the discovery of a novel group of peptides within the genome of mitochondria, the powerhouses of the cell. This groundbreaking discovery was made by our ...

Mitochon Pharmaceuticals, Inc.

Mitochon was founded in 2014 with the mission to develop treatments for insidious diseases through the modulation of mitochondrial physiology, with applications to neurodegeneration, neuromuscular, and developmental diseases. Mitochon’s lead programs, MP101 and MP201, specifically harnesses the power of the mitochondria to provide broad neural protect...

More From BioPortfolio on "Cytochrome P450 11B2 Mitochondrial Aldosterone Synthase Cytochrome P450Aldo"

Quick Search


Corporate Database Quicklinks